Pristimerin induces apoptosis in imatinib-resistant chronic myelogenous leukemia cells harboring T315I mutation by blocking NF-κB signaling and depleting Bcr-Abl

BACKGROUND: Chronic myelogenous leukemia (CML) is characterized by the chimeric tyrosine kinase Bcr-Abl. Bcr-Abl-T315I is the notorious point mutation that causes resistance to imatinib and the second generation tyrosine kinase inhibitors, leading to poor prognosis. CML blasts have constitutive p65...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Egile Nagusiak: Lu, Zhongzheng, Jin, Yanli, Chen, Chun, Li, Juan, Cao, Qi, Pan, Jingxuan
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: BioMed Central 2010
Gaiak:
Research
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC2893099/
https://ncbi.nlm.nih.gov/pubmed/20482842
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/1476-4598-9-112
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak